Google Secures Pentagon AI Deal for Classified Projects 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
VANCOUVER, British Columbia, April 25, 2017 -- Novelion Therapeutics, Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, announced today that the company will participate in the Bloom Burton & Co. Healthcare Investor Conference in Toronto. Chief Executive Officer Mary Szela is scheduled to present on Monday, May 1, 2017 at 10:00 a.m. EDT.
The presentation will be webcast live and may be accessed for up to 90 days following the conference by visiting the “Investors” section of Novelion’s website, www.novelion.com.
About Novelion Therapeutics
Novelion Therapeutics is a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases. Novelion has a diversified commercial portfolio through its indirect subsidiary, Aegerion Pharmaceuticals, Inc., which includes MYALEPT® and JUXTAPID®, and is also developing zuretinol acetate for the treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes. The company seeks to advance its portfolio of rare disease therapies by investing in science and clinical development.
CONTACT: Amanda Murphy, Director, Investor Relations & Corporate Communications Novelion Therapeutics 857-242-5024 [email protected]
